FDA Lifts U.S. Clinical Holds on CARsgen® According to Investing.com

FDA Lifts U.S. Clinical Holds on CARsgen® According to Investing.com

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has recently announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on clinical trials of three of its CAR T-cell therapies in the United States. These therapies include zevorcabtagene autoleucel (zevor-cel, CT053), which targets BCMA, satricabtagene autoleucel (satri-cel, CT041), targeting Claudin18.2, and CT071, … Read more

Investing.com reports Valaris’ strong Q3 performance with solid cash flow and EBITDA

Investing.com reports Valaris’ strong Q3 performance with solid cash flow and EBITDA

Valaris PLC (VAL), a leader in offshore drilling services, reported a solid financial performance in its Third Quarter 2024 Earnings Call, underscoring a strong market presence and future growth potential. CEO Anton Dibowitz and CFO Chris Weber shared that the company generated $111 million in free cash flow and achieved an adjusted EBITDA of $150 … Read more

Capital Properties, Inc. Announces Standard Quarterly Dividend By Investing.com

FDA Lifts U.S. Clinical Holds on CARsgen® According to Investing.com

PROVIDENCE, R.I., Oct. 31, 2024 /PRNewswire/ — Capital Properties, Inc. (OTCQX: CPTP) announced that during its regular quarterly meeting held on October 30, 2024, the Board of Directors approved the declaration of a regular quarterly dividend of $0.07 (seven cents) per share on the Company’s outstanding Class A Common Shares (6,599,912). This dividend will be … Read more

Herbalife Achieves Q3 Guidance with $1.2B in Net Sales, Reports Investing.com

Herbalife Achieves Q3 Guidance with .2B in Net Sales, Reports Investing.com

At this point, I will now turn the call over to Michael Johnson, our Chairman and CEO. Michael, please go ahead. Michael Johnson: Thank you, Erin, and good afternoon, everyone. I am pleased to report that Herbalife had a solid performance in the third quarter of 2024, meeting our net sales guidance of $1.2 billion … Read more

Samsung’s HBM advancements lead to Micron’s decline, reports Investing.com.

Samsung’s HBM advancements lead to Micron’s decline, reports Investing.com.

Investing.com — Shares of Micron Technology (NASDAQ: MU) fell by 2.5% on Thursday following an announcement by Samsung Electronics (KS: 005930) regarding advancements in its high-bandwidth memory (HBM) chip supply efforts. The news indicated that Samsung’s progress in key qualification tests could potentially allow the company to compete more effectively in the AI-driven semiconductor market, … Read more

Oppenheimer optimistic about KLA stock, labeling it the “Microsoft of metrology” According to Investing.com

FDA Lifts U.S. Clinical Holds on CARsgen® According to Investing.com

On Thursday, Oppenheimer revised its position on KLA Corporation (NASDAQ:KLAC), upgrading the stock from Perform to Outperform and raising the price target to $850 from the previous $750. This move comes after KLA’s first-quarter results for fiscal year 2025 exceeded expectations, leading the firm to increase its fiscal year 2025-2026 (June) estimates by 2%. The … Read more

CEO of Paycom offloads shares valued at $655,996 according to Investing.com

CEO of Paycom offloads shares valued at 5,996 according to Investing.com

Chad R. Richison, the CEO, President, and Chairman of Paycom Software, Inc. (NYSE: PAYC), recently carried out a series of stock sales amounting to $655,996. These transactions took place on October 29, 2024, at various price points ranging from $166.18 to $168.96 per share. The sales were executed under a joint Rule 10b5-1 trading plan … Read more

Investing.com reports Goldman Sachs’ Buy rating on Meta with a price target of $636.

FDA Lifts U.S. Clinical Holds on CARsgen® According to Investing.com

“ On Wednesday, Goldman Sachs reiterated its Buy rating on Meta Platforms Inc. (NASDAQ: NASDAQ:), maintaining a price target of $636.00 for the stock. The financial institution’s analysis came after Meta’s third-quarter earnings report for 2024, which showed revenues slightly exceeding Goldman Sachs and other Wall Street estimates, falling within the upper range of the … Read more

Director of BlackRock Municipal Income Trust II purchases $107 worth of stock according to Investing.com

Director of BlackRock Municipal Income Trust II purchases 7 worth of stock according to Investing.com

Stayce D. Harris, a director at BlackRock (NYSE:) Municipal Income Trust II (NYSE:BLE), recently purchased 10 shares of the company’s common stock. The transaction, which took place on October 29, saw Harris acquire the shares at an average price of $10.7342 per share, totaling $107. This acquisition now brings Harris’s total holdings to 10 shares, … Read more